Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
Status:
Terminated
Trial end date:
2018-01-10
Target enrollment:
Participant gender:
Summary
The objective of this clinical study is to evaluate the safety and efficacy of three
different doses of BHR-200 (0.36% transdermal estradiol gel) compared to placebo for the
maintenance of testosterone (T) suppression in men with advanced androgen-sensitive prostate
cancer.